Skip to content
Screener

Vertex Pharmaceuticals VRTX EV / EBITDA

EV / EBITDA at other companies

Travere Therapeutics, Inc. logo
Travere Therapeutics, Inc.TVTX
166.4×—
AbbVie logo
AbbVieABBV
19.8×—

Other financials

Income statement

See full
Revenue$3.3B+12.5%
Gross profit$2.8B+11.2%
Operating income$1.2B+8.3%
Net income$1.1B+6.5%
EPS (diluted)$4.31+8.0%

Balance sheet

See full
Cash & equivalents$7.9B+57.6%
Total debt$2.0B+29.5%
Total equity$20.2B+17.9%
Total assets$27.4B+14.1%

Cash flow

See full
Operating cash flow$1.4B+74.4%
CapEx$133.4M+228%
Free cash flow$1.3B+66.4%

Valuation

See full
Market cap$122.89B+24.3%
Enterprise value$117.01B+22.6%
P/E27.9×—
P/S9.8×+1.1×

Profitability

See full
Gross margin86%-0.1pp
Operating margin38%—
Net margin35%—
FCF margin30.4%+20.2pp

Returns & leverage

See full
Return on equity23.5%—
Debt / equity0.1×0.0×
Current ratio3.2×+0.7×

Where this comes from

Calculated from Vertex Pharmaceuticals’s reported figures.

enterprise value/ebitda=22.4×

Based on the most recent quarter.

The source filing: Vertex Pharmaceuticals’s 10-Q, filed May 5, 2026. Open the filing →

Filed
May 5, 2026, 4:08 PM EDT
Fiscal quarter
Q1 FY2026
Calendar quarter
Q1 2026
Accession
0000875320-26-000173

FAQ

What is Vertex Pharmaceuticals's EV / EBITDA?
Vertex Pharmaceuticals (VRTX) reported EV / EBITDA of 22.4× in Q1 2026.
What is the long-term trend for Vertex Pharmaceuticals's EV / EBITDA?
Over 5 years (2020 to 2025), Vertex Pharmaceuticals's EV / EBITDA has grown at a 5.4% compound annual growth rate (CAGR), from 19.6× to 25.5×.
What does EV / EBITDA mean?
Enterprise value (market cap plus total debt minus cash) at the quarter end divided by trailing-twelve-month EBITDA. A capital-structure-neutral valuation multiple.

Ask your AI about Vertex Pharmaceuticals's ev / ebitda.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude